Drug Discovery & DDS– category –
-
FDA Grants Dual Breakthrough and Orphan Designations to Volixibat for PSC-Related Cholestatic Pruritus
HCPLive USA Overview The U.S. FDA has granted both Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) to volixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, for the treatment of cholestatic p... -
ReCode Therapeutics Secures Funding, Partners with Gene Editing Firm to Fast-Track Cystic Fibrosis Gene Therapy with SORT LNP Platform
BioSpace (via Business Wire) USA Overview ReCode Therapeutics has announced new funding from the Cystic Fibrosis Foundation and a strategic partnership with a leading gene editing company. These initiatives will accelerate the developmen... -
Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development
Las Vegas Sun News (via Business Wire) USA Overview Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Can... -
Monte Rosa’s AI-Powered Molecular Glue Degrader MRT-6160 Achieves >90% VAV1 Degradation and Potent Cytokine Suppression in Phase 1, Prompting Multiple Novartis-Led Phase 2 Trials
Quartr Sweden Overview Monte Rosa Therapeutics has announced that its AI-driven QuEEN platform's molecular glue degrader (MGD) MRT-6160 achieved over 90% VAV1 protein degradation and potent cytokine suppression in Phase 1 trials. This su... -
Biopharma’s Bottleneck: Critical CDMO Capacity Shortage Hampers Advanced Therapy Development
Contract Pharma USA Overview A severe capacity crunch within Contract Development and Manufacturing Organizations (CDMOs) is impeding the biopharmaceutical industry. Recent data reveals nearly half of biopharma firms struggle to secure C... -
Nanomedicine Conquers Glioblastoma’s Blood-Brain Barrier: Revolutionizing Treatment via Targeted Delivery, Stimuli-Responsiveness, and AI
Drug Target Review UK Overview Nanomedicine is emerging as a critical solution to overcome the formidable blood-brain barrier (BBB) in treating glioblastoma (GBM), the most aggressive brain tumor. Researchers are developing advanced nano... -
Peking University Unveils SynTar LNPs: A Precision Breakthrough for Targeted mRNA Lung Delivery
SINOPEG China Overview Researchers at Peking University have developed an innovative SynTar lipid nanoparticle (SynTar LNP) platform, overcoming a critical bottleneck in targeted mRNA delivery to the lungs. This system significantly enha... -
Dana-Farber Unveils Platform to Unlock ‘Undruggable’ Targets with Novel Molecular Glue Degraders, Discovering First Metabolically Activated Agents
Facebook (reposting Dana-Farber Cancer Institute news) USA Overview Researchers at Dana-Farber Cancer Institute have developed an innovative, scalable platform for systematically discovering molecular glue degraders (MGDs) that target pr... -
乳がん治療向け次世代ADCの開発課題と進歩：送達生物学の最適化が成功の鍵
PubMed (Expert Opinion on Drug Delivery) USA Overview Expert Opinion on Drug Deliveryに掲載されたレビューは、乳がんの治療抵抗性疾患に対する次世代抗体薬物複合体（ADC）の開発における進歩と課題を統合的に評価しました。本レビューは、ADCの設計... -
FDA Designates Washington University’s WU-CART-007 as Breakthrough Therapy for T-Cell Malignancies: Allogeneic Anti-CD7 CAR T-Cell Therapy Achieves 73% Complete Remission
Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine USA Overview The FDA has granted Breakthrough Therapy Designation (BTD) to WU-CART-007, an allogeneic anti-CD7 CAR T-cell therapy developed by Washington University Schoo...
